Experimental Drug Retatrutide Shows Significant Weight Loss and Blood Sugar Improvement in Type 2 Diabetes Trial
A new experimental drug, retatrutide, has demonstrated significant efficacy in reducing weight and improving blood sugar levels in adults with type 2 diabetes and overweight or obesity. The drug, a triple-agonist medication, acts on three different hormone receptors: glucagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide (GIP), and glucagon (GCG). This mechanism distinguishes it from existing GLP-1 medications like semaglutide (Ozempic) and tirzepatide (Mounjaro), which act on one or two receptors, respectively. The latest clinical trial, published in The Lancet, involved nearly 1,200 participants who were randomly assigned to receive weekly doses of retatrutide (4 mg, 9 mg, or 12 mg) or a placebo. After 80 weeks, participants on retatrutide experienced substantial weight loss, with those on the 12 mg dose losing an average of 18.8 percent of their starting weight. Almost half of the participants on the highest dose lost 20 percent of their starting weight, and about 30 percent lost at least 25 pe...